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Abstract
Background:  Comparison of data produced on different microarray platforms often shows
surprising discordance. It is not clear whether this discrepancy is caused by noisy data or by
improper probe matching between platforms. We investigated whether the significant level of
inconsistency between results produced by alternative gene expression microarray platforms could
be reduced by stringent sequence matching of microarray probes. We mapped the short oligo
probes of the Affymetrix platform onto cDNA clones of the Stanford microarray platform.
Affymetrix probes were reassigned to redefined probe sets if they mapped to the same cDNA
clone sequence, regardless of the original manufacturer-defined grouping. The NCI-60 gene
expression profiles produced by Affymetrix HuFL platform were recalculated using these redefined
probe sets and compared to previously published cDNA measurements of the same panel of RNA
samples.
Results:  The redefined probe sets displayed a substantially higher level of cross-platform
consistency at the level of gene correlation, cell line correlation and unsupervised hierarchical
clustering. The same strategy allowed an almost complete correspondence of breast cancer
subtype classification between A f f y m e t r i x  g e n e  c h i p  a n d  cDNA microarray derived gene
expression data, and gave an increased level of similarity between normal lung derived gene
expression profiles using the two technologies. In total, two Affymetrix gene-chip platforms were
remapped to three cDNA platforms in the various cross-platform analyses, resulting in improved
concordance in each case.
Conclusion: We have shown that probes which target overlapping transcript sequence regions
on cDNA microarrays and Affymetrix gene-chips exhibit a greater level of concordance than the
corresponding Unigene or sequence matched features. This method will be useful for the
integrated analysis of gene expression data generated by multiple disparate measurement
platforms.
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Background
The first years of microarray analysis of human cancer
samples produced several promising results, introducing
complex gene expression profiles for diagnostics and pre-
dicting disease outcome [1]. However, initial enthusiasm
was replaced by uncertainty when classifiers produced for
the same type of diseases in various studies shared few if
any of the same marker genes [2]. Although microarray
results are often reproducible for a single platform, incon-
sistencies in sensitivity, cross hybridization, and splice
variant specificity may render the transfer of results
between microarray platforms problematic.
One of the difficulties in the cross platform comparison of
microarray data is to ascertain that probes on the various
platforms aimed at the same gene do in fact quantify the
same mRNA transcript. The various strategies to match
probes between different platforms can be constrained by
the amount of information provided by the manufactur-
ers of the given microarray. Initially, actual probe
sequence information was not released; therefore, probe
matching could be based only on gene identifiers such as
the Unigene ID. This strategy is known to produce a sig-
nificant number of incorrect pairings [3]. As partial or
complete probe sequence information has become avail-
able, more accurate strategies can now be implemented.
In a recent study, we compared several Affymetrix plat-
forms (for which probe sequence information was availa-
ble) to the Agilent Human 1 cDNA microarray platform
[4]. Probe sequence information was unavailable for the
Agilent platform except for a 100 base lead sequence at
one end of each cDNA probe. Using this information, we
queried whether the Affymetrix probes and the 100 base
lead sequence could be mapped to a single Unigene tran-
script. Unigene matched probes across the two platforms
that failed this sequence mapping test showed a signifi-
cantly lower expression correlation across the two micro-
array platforms [4]. However, the lack of complete cDNA
sequence information precluded determination of the
actual sequence overlap level with high certainty.
In contrast to the Agilent probes, short sequences from
both the 5' and 3' ends are generally available for clones
on Stanford cDNA microarrays. Using these sequences to
infer the complete clone sequence, we show that the level
of probe sequence overlap is highly related to the gene
expression concordance between the Affymetrix and
cDNA microarray platforms. Eliminating non-overlap-
ping probes allowed us to extract more consistent results
from cancer associated gene expression data produced by
different platforms and in different institutions.
Results
Depending on availability or the set of genes to be quan-
tified, large scale gene expression profiling studies have
used different versions of chips of a given microarray plat-
form. For the data sets analyzed in this study two types of
Affymetrix chips were used: the HuFL oligo chips and the
U95Av2 chips. These contain 20 and 16 oligo probes per
probe set, respectively. For the cDNA microarray studies,
the pool of actual clones shows a very high level of diver-
sity between various studies. Therefore, the exact number
of overlapping probes depended on both the specific gen-
eration of Affymetrix platform and the set of cDNA clones
to which it was mapped. A summary of these data is listed
in Table 1.
Comparison of cDNA and Affymetrix expression 
measurements
Because cDNA microarray measurements are typically
reported as the log ratio of an experimental (Cy5) and
control (Cy3) channel, direct comparison with single-
channel Affymetrix data required that one of the two data
sources be converted to a scale compatible with the other.
Because the spot-size on robotically spotted cDNA micro-
arrays can vary substantially, considering only the experi-
mental channel would have given expression
measurements prone to probe-quantity artifacts. On the
other hand, without direct measurement on the Affyme-
trix platform of the control RNA used in the cDNA hybrid-
ization, it was impossible to replicate exactly the reference
response level of each measurement feature.
We attempted to address this difficulty by assuming that
the reference RNA batches chosen for each cDNA hybrid-
ization uniformly reflect the diversity of experimental
transcript populations and therefore that the mean of a
gene's measured expression level across all experiments
may serve as a reference for the normalization of Affyme-
trix data (methods). We verified that the mean expression
measured by each Affymetrix array did not vary substan-
tially (max- min < 0.25).
Sequence-overlapping probes give greater cross-platform 
consistency for the NCI-60 panel
The NCI-60 cell line panel consists of sixty well character-
ized human tumor cell lines derived from patients with
leukaemia, melanoma, and lung, colon, central nervous
system, ovarian, renal, breast and prostate cancers. This
cell line panel has been developed by the Developmental
Therapeutics Program of the National Cancer Institute
and routinely used to screen potential anticancer drugs
[5].
The gene expression profiles of the NCI-60 cell line panel
measured by cDNA microarray and by Affymetrix HuFL
oligo chips constitutes a unique data source. To the best ofBMC Bioinformatics 2005, 6:107 http://www.biomedcentral.com/1471-2105/6/107
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our knowledge, it is the only publicly available dataset in
which replicates of a large number of diverse RNA samples
have been quantified by these two microarray platforms.
Affymetrix microarray probe sets were classified based on
their shared sequence identity across the two platforms.
Since the actual number of overlapping probes can be
between 0 and 20, a large number of potential stratifica-
tion schemes can be implemented. However, for a clear
presentation of results we chose to compare the following
classes representing different levels of shared identity: a)
Affymetrix probe sets that share a Unigene ID with a
cDNA clone. (termed Shared Unigene probes) b) Affyme-
trix probe sets containing probes that could be sequence-
matched to the same transcript sequence as the cDNA
clone, but for which no Affymetrix probe actually overlaps
the cDNA clone sequence (termed Shared Transcript
probes); c) Affymetrix probe sets with 1 to 10 probes
sequence overlapping with the cDNA clone (termed Par-
tially Overlapping probes); d) Affymetrix probe sets with
20 (i.e. all) probes sequence overlapping with the cDNA
clone (termed Completely Overlapping probes); e) alt-
CDF or "redefined probe sets" for which all probes across
the entire array that matched to a given cDNA clone insert
were used to define a new derivative probe set. This new
probe set may contain only a subset (even a single probe)
of an original probe set; in other cases probes across sev-
eral original probe sets were joined into the new derivative
probe set (fig 1). For "partially overlapping" and "com-
pletely overlapping" probes (classes c and d), the entire
original probe set was used for calculating gene expression
levels, whereas for the "redefined" probe sets (class e)
only the sequence mapped probes were retained.
Figure 2 demonstrates the correlation between the
Affymetrix and cDNA microarray measurements for the
various types of matched probes across the two platforms.
Increasing the number of overlapping Affymetrix probes
ensures increased cross-platform consistency both for
matched genes and matched cell-lines. Additionally, con-
cordance was greatest when only sequence-overlapping
probes were used by redefining probe sets, even though in
some cases only a single Affymetrix probe was considered.
Redefined probes and completely overlapping probes
showed the highest concordance levels. (The cumulative
correlation distributions showed little difference, however
the former method allowed a 4-fold increase in the
number of available genes.) These results imply that
probes targeting identical transcript sequence regions give
substantially stronger concordance than probes that target
identical contiguous transcript molecules at different
sequence regions. In order to further investigate the effect
of direct sequence overlap we examined the performance
of Affymetrix probe sets that can be sequence mapped to
the same transcript molecule but show no actual overlap
with the cDNA clone insert ("shared transcript" probes,
class b). These probe sets showed the lowest correlation.
This might be due to a number of factors including the
presence of splice variants, the probes being subject to dif-
ferent cross-hybridization patterns, or incorrect clone
sequence predictions.
Figure 2A also shows, however, that a significant number
of probes matched by complete sequence overlap show
rather poor correlation (around zero) across the two plat-
forms. The same applies to redefined probe sets. Because
we used Pearson correlation as our concordance metric,
we expect genes for which the signal fluctuation is below
the resolution of the measurement platform to have low
levels of concordance, (since the corresponding
correlations will be made between noise.) We investigated
the effect of removing genes with low levels of variation
across the cell-lines on the cross-platform concordance
(Fig. 3). Specifically, we removed genes from the Affyme-
trix dataset with standard deviations below 0.388, (repre-
senting the 50th percentile of standard deviation in the full
Unigene-mapped dataset.) We removed genes from the
cDNA dataset with standard deviations below 0.265, (rep-
resenting the 50th percentile of standard deviation in the
full cDNA dataset.) Matched gene and cell-line concord-
ance was then assessed as described using the genes
remaining in both datasets (Fig. 3).
Table 1: Summary of mapping cDNA microarray features to probes on Affymetrix gene-chips.
NCI-60 – HuFL Brc 8k – HuFL Brc8k – U95Av2 Lung – U95Av2
Total cDNA clones 9707 8820 8820 22691
Clones with both reads sequenced 6222 7015 7015 18645
Clones with predicted insert region 4639 6354 6354 14813
Total Probe-sets defined 1765 2403 3103 4597
Total (perfect match) probes on Affymetrix platform 131541 131541 199084 199084
Total mapped probes 26347 37559 48250 70001
Probes mapped to multiple clones 904 3224 4019 26765
Number of probe-sets with > 1 Affymetrix "probe-set" represented 115 310 664 888BMC Bioinformatics 2005, 6:107 http://www.biomedcentral.com/1471-2105/6/107
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Composition of redefined Affymetrix probe-sets based on overlap with cDNA clone insert sequence Figure 1
Composition of redefined Affymetrix probe-sets based on overlap with cDNA clone insert sequence. Stacked histograms show 
the distribution of probe-set size for sets consisting of a single Affymetrix-defined probe-set (black) and for those comprised of 
probes originally grouped into separate probe-sets by Affymetrix (gray). A, NCI-60 10 k cDNA microarray to HuFL alternative 
CDF. B, Breast cancer 8 k cDNA microarray to HuFL alternative CDF. C, Breast cancer 8 k cDNA microarray to HG-U95Av2 
alternative CDF. D, Lung cancer 22 k cDNA microarray to HG-U95Av2 alternative CDF.BMC Bioinformatics 2005, 6:107 http://www.biomedcentral.com/1471-2105/6/107
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Sequence-overlapping probes give greater cross-platform concordance for the NCI-60 panel Figure 2
Sequence-overlapping probes give greater cross-platform concordance for the NCI-60 panel. (A) Pearson correlation coeffi-
cient was calculated for each gene between its expression values measured on the Affymetrix Hu6800 platforms and its 
expression values measured on the Stanford cDNA microarray across sixty cell lines of the NCI-60 panel. The figure shows 
the cumulative distribution of the Pearson correlation coefficients for all genes analyzed. The five different curves reflect the 
level of cross-platform consistency of probe sets with various levels of overlap between the two microarray platforms. 
Matched gene measurements across the two platforms showed higher correlation when greater numbers of probes in the 
Affymetrix probe sets overlapped the insert region of the cDNA clone. The highest correlation was attained when only those 
Affymetrix probes overlapping the insert-sequence of a given cDNA clone were retained. Measurements for which the probes 
targeted the same transcript as the cDNA clone, but did not overlap the clone sequence, showed the lowest correlation. (B), 
Pearson correlation coefficient was calculated across all genes for each matched sample pair profiled by the Affymetrix Hu6800 
platform and by the Stanford cDNA microarray. The figure shows the cumulative distribution of the Pearson correlation coef-
ficients for the sixty cell lines of the NCI-60 panel. Matched cell-line measurements showed identical stratification of correla-
tion levels by feature-matching criteria.BMC Bioinformatics 2005, 6:107 http://www.biomedcentral.com/1471-2105/6/107
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Effect of standard deviation filtering on cross-platform NCI-60 concordance Figure 3
Effect of standard deviation filtering on cross-platform NCI-60 concordance. Genes are filtered removing those with low 
standard deviations across the 60 cell-lines (methods.) Matching features are determined and concordance assessed as in Fig-
ure 1.BMC Bioinformatics 2005, 6:107 http://www.biomedcentral.com/1471-2105/6/107
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As expected, removing these genes substantially increased
both gene and cell-line concordance (Fig. 3). This
improvement was substantially greater than that obtained
by filtering genes based on mean expression (data not
shown). Specifically, the range of median gene correlation
increased from approximately 0.2 – 0.4 to 0.4 – 0.6. Inter-
estingly, filtering did not give a substantial improvement
near the low end of the distribution, suggesting that some
correlations of < 0.1 may be due to incorrect mappings or
non-functional probes.
Finally, we noted that "complete overlap" matched pairs
performed better than redefined probe sets after standard
deviation filtering. This may be due to a number of fac-
tors, such as the potentially small number of probes inter-
rogating a given transcript level (in some cases only a
single probe.) Alternatively, the redefined probe sets may
contain spurious probes in cases where a false-positive
clone sequence prediction led to the combination of sev-
eral Affymetrix-defined probe sets. In any case, the ~4-fold
increase in the number of mapped genes available
through redefined probe sets may offset the small reduc-
tion in concordance.
Highly correlated genes are expected to produce a more
reproducible unsupervised classification of the cell lines
than that derived from a larger pool of genes with less cor-
relation. This can be evaluated in several ways. For exam-
ple, the hierarchical classification trees derived from the
Affymetrix gene chip and cDNA microarray based meas-
urements can be visually compared. Improved reproduci-
bility of classification is indicated by the fact that more
cell lines show similar or identical classification on the
two hierarchical trees (fig 4).
Encouraged by our initial success, we merged the Affyme-
trix and cDNA microarray based gene expression profiles
and hierarchically clustered the composite data set. More
consistent measurements of gene expression across the
two platforms would result in a greater number of
instances in which the measurements of the same cell-line
cluster together. In addition, co-clustering of cell lines of
similar origin also provides circumstantial evidence that
the gene expression profiles accurately reflect a certain
tumor subtype.
Indeed, hierarchical clustering of the combined datasets
resulted in a greater number of matched cell-lines cluster-
ing together when only sequence-overlapping measure-
ments were used (fig 5). The majority of matched cell lines
are more correlated to one another than to any other cell
line from either platform. This was not the case when the
expression measurements were Unigene-matched (fig
5A).
We were somewhat disconcerted by the fact that some of
the cell lines showed a completely different localization
on the two hierarchical trees. For example, the colon can-
cer cell line HT-29 clusters together with other colon can-
cer cell lines on the cDNA microarray derived tree but it is
placed in a different cluster on the Affymetrix gene chip
based classification tree (fig 4). An obvious explanation
for this discrepancy would be the failure of the Affymetrix
gene chip based measurement. Since no replicates were
produced for any of the measurements, there is no statis-
tically sound way of evaluating the quality of any of the
gene expression profiles except by some circumstantial
measures. For example, most cell lines had cross-platform
correlation coefficients larger than 0.2 (Fig 2B). HT-29
was the single outlier with correlation consistently near 0.
We obtained an alternative measurement of the same cell
line based on an HG-U133A Affymetrix gene chip (a gen-
erous gift of Avalon Pharmaceuticals Inc.) We extracted a
gene expression profile using the "redefined probe sets"
strategy. This gene expression vector produced a much
higher correlation coefficient (0.208) with the corre-
sponding cDNA microarray measurements.
Sequence overlapping measurements improve cross-
platform classification of breast cancer subtypes
We were seeking further confirmation for our method
using gene expression profiles derived from various
human tissue samples. These data sets do not allow highly
controlled side-by-side comparisons such as the above
presented analysis using  in vitro cell lines. Therefore, we
needed to rely on "indirect" measures of cross-platform
consistency, such as classification reproducibility.
Namely, we investigated whether sequence matching of
probes would enable us to reproduce the classification of
primary breast tumor derived gene expression profiles
produced by different microarray platforms.
A breast-cancer subtype classifier was derived from a
cohort of patients profiled on cDNA microarrays [1]. This
classifier transferred to Affymetrix HuFL gene expression
data [6] only to a limited extent [7]. Recently, we
improved on those results by using only those Affymetrix
and cDNA probes that could be mapped to the same tran-
script [4]. This earlier publication, however, did not
involve the selective use of only those oligo probes that
actually matched the cDNA clone. Here we introduced the
use of "redefined probe sets" as described in the methods.
This was coupled with an advanced normalization
method, RMA [8], leading to a strong overall improve-
ment over the original results of Sørlie et al [7] (fig 6). In
particular, with two exceptions, all samples could be
assigned to a breast cancer subtype defined by the cDNA
microarray derived centroids. In addition, more than 70%
of all samples clustered in their own well-defined clusters.BMC Bioinformatics 2005, 6:107 http://www.biomedcentral.com/1471-2105/6/107
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Conserved clustering pattern of the NCI-60 cell lines profiled using cDNA microarray and Affymetrix gene chips Figure 4
Conserved clustering pattern of the NCI-60 cell lines profiled using cDNA microarray and Affymetrix gene chips. Data was 
normalized as described (methods). Average linkage Pearson correlation hierarchical clustering was computed for each data-
set. Cell line names are colored according to cancer type.BMC Bioinformatics 2005, 6:107 http://www.biomedcentral.com/1471-2105/6/107
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Improved hierarchical clustering of combined NCI-60 cell-lines profiled by Affymetrix gene-chip and cDNA microarray by  sequence-overlapping probe measurements Figure 5
Improved hierarchical clustering of combined NCI-60 cell-lines profiled by Affymetrix gene-chip and cDNA microarray by 
sequence-overlapping probe measurements. The gene expression profiles obtained for the sixty cell lines by the Affymetrix 
gene chips and the Stanford cDNA microarray platform were pooled after data transformation as described in the text. Gene 
expression data by the two different platforms were matched by either Unigene ID matching or by redefining the Affymetrix 
probe sets based on the sequence overlap criteria of the probes. The pooled gene expression profiles were subjected to aver-
age linkage hierarchical clustering. Matched cell-lines from the two platforms which cluster together are marked by red 
branches in the dendrogram. (A) Unigene-matched measurements tended to cluster the cell-lines by measurement platform, 
and produced only 28 instances of matched cell-lines clustering together. (B) Sequence-overlapping probe measurements pro-
duced more (43) instances of matched cell-lines from each platform clustering together.BMC Bioinformatics 2005, 6:107 http://www.biomedcentral.com/1471-2105/6/107
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Furthermore, we compared the transfer of the cDNA-
based classifier [7] to two additional cohorts of breast can-
cer samples profiled on Affymetrix HG-U95Av2 gene-
chips [9,10], using both the 'shared Unigene' (fig 7A) and
'redefined probe sets' (fig 7B) to match measurements
(see methods). Since true classes are usually not known a
priori for novel cancer subtypes, we focused our attention
on a subtype where gene expression profiles associated
with an independent immunohistochemical marker: Her-
2 / erbB2 status. Significantly, the classification based on
'redefined probe sets' contains a larger and more coherent
ERBB2+ subtype cluster than that based on shared Uni-
gene identifier. The validity of this cluster was substanti-
ated by the immunohistochemical assessment of Her-2
status (available only for the Santorini cohort); all of the
tested samples in this cluster stained positive for Her-2
amplification.
Sequence-overlapping measurements improve cross-
platform similarity of normal lung samples
Finally, we evaluated our sequence-overlap probe set
redefinition method on a third cDNA platform. In this
case, we evaluated the cross-platform similarity of normal
lung samples profiled on cDNA microarrays [11] and
Affymetrix HG-U95Av2 gene chips [12]. These two inde-
pendent data sets contain normal samples from different
patients. However, a robust gene expression profile was
detected in both studies for the normal lung tissue sam-
ples [11,12]. If this robust, normal gene expression profile
is accurately measured by both microarray platforms, then
a high Pearson correlation coefficient would be expected
between the normal samples, independently from the
microarray platform used for a given tissue sample. There-
fore, we calculated the correlation coefficient between
each possible pair of normal gene expression profiles
across the two platforms. Two probe matching strategies,
the Unigene and sequence-overlap based mappings were
compared (fig 8). The significance of the observed
increase in cross-platform correlation was assessed at p =
0.0002 (methods), further highlighting the advantage of
using only sequence-overlapping measurements for cross-
platform comparison.
Discussion
Despite the fact that all microarray technologies are based
on the same basic principle of complementary hybridiza-
tion, various probe selection strategies aim to achieve
optimal probe performance given the technological con-
straints using fundamentally different strategies. In order
to be able to plan long-term microarray based experimen-
tal strategies, end users have hoped either for a clearly
superior technology to emerge, perhaps supported by a
large number of independent validations, or for a high
level of cross-platform consistency when the same type of
RNA is expression profiled on different platforms. The lat-
ter being true would mitigate the risk of committing to a
less accurate technology. Unfortunately, this hope has not
been fulfilled yet. The limited number of independent val-
idations published so far suggested a similar level of accu-
racy, or lack thereof, for the most widely used platforms
[13-15], and the first cross platform comparison studies
revealed an alarming level of inconsistency between plat-
forms such as the cDNA microarray and the Affymetrix
oligo chip [16]. This provided little guidance for prospec-
tive users on how to choose the technology best suited for
their experiments.
Increased efficiency of breast cancer subtype classification transfer from cDNA microarray to Affymetrix HuFL gene-chip  tumor-profiles by sequence-overlapping probe measurements Figure 6
Increased efficiency of breast cancer subtype classification transfer from cDNA microarray to Affymetrix HuFL gene-chip 
tumor-profiles by sequence-overlapping probe measurements. Tumor samples profiled on the Affymetrix platform were classi-
fied according to their correlation with the set of subtype median-centroids derived from cDNA microarray measurements 
(see methods). The classified samples were then hierarchically clustered using Pearson correlation and average-linkage agglom-
eration. Affymetrix measurements matched to cDNA centroids by sequence-overlap of probe features produced more coher-
ent classifications than those obtained in the original transfer (Sørlie), specifically, more coherent Luminal A and ERBB2+ 
subtype clusters.BMC Bioinformatics 2005, 6:107 http://www.biomedcentral.com/1471-2105/6/107
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Cross platform consistency is an imperfect tool with
which to validate microarray platforms. Lack of consist-
ency can be caused by the inferior performance of either
one or both platforms, without clear indication of their
relative merit. On the other hand, highly similar results
across platforms could be simply caused by consistent
cross-hybridization patterns without either platform
measuring the true level of expression. Nevertheless, a
high level of cross platform consistency is desirable. If
both platforms perform accurate measurements then
cross platform consistency will automatically follow. In
other words, cross platform consistency is the sine qua non
of accurate microarray measurements but by itself will not
validate the technology.
Cross platform inconsistencies can be caused by at least
two major factors: a) significant differences in noise struc-
ture between technologies; b) differential hybridization of
Increased efficiency of breast cancer subtype classification transfer from cDNA microarray to Affymetrix HG-U95Av2 gene- chip tumor-profiles by sequence-overlapping probe measurements Figure 7
Increased efficiency of breast cancer subtype classification transfer from cDNA microarray to Affymetrix HG-U95Av2 gene-
chip tumor-profiles by sequence-overlapping probe measurements. Tumor samples profiled on the Affymetrix platform were 
classified according to their correlation with the set of subtype median-centroids derived from cDNA microarray measure-
ments (see methods). The classified samples were then hierarchically clustered using Pearson correlation and average-linkage 
agglomeration. (A), Affymetrix measurements matched to the cDNA centroids by Unigene identifier. (B), Affymetrix measure-
ments matched to cDNA centroids by sequence-overlap of probe features produced more coherent classifications. In particu-
lar, the large ERbB2+ subtype cluster (upper left) is mostly absent from the unigene-based classification. The significance of this 
cluster is supported by the observation that all tumors in this cluster for which Her-2 amplification was assessed by immuno-
histochemistry were designated positive.BMC Bioinformatics 2005, 6:107 http://www.biomedcentral.com/1471-2105/6/107
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homologous probes designed to measure the same gene
on various platforms. It has been shown that the most
consistent results across different versions of the
Affymetrix DNA chips are provided by identical probes
[17]. Probes with less or no sequence overlap, even if tar-
geting the same gene at different locations, show substan-
tially lower consistency. Therefore, sequence matching
Increased cross-platform similarity of normal lung samples by sequence-overlapping probe measurements Figure 8
Increased cross-platform similarity of normal lung samples by sequence-overlapping probe measurements. Shown are the 
cumulative distributions of the 5 × 17 cross-platform sample correlations (see methods.) substantially greater similarity is 
observed when only sequence-overlapping probe measurements are retained (black curve.)BMC Bioinformatics 2005, 6:107 http://www.biomedcentral.com/1471-2105/6/107
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probes provides a strategy for dissecting the sources of
cross platform inconsistency.
There are only a few publicly-available data sets that allow
comprehensive cross platform comparison of a relatively
large number of RNA samples with ample probe sequence
information available. The most widely studied of these is
the gene expression profiling of the NCI-60 cell line panel
produced by the Affymetrix and cDNA microarray tech-
nologies [5,16,18-20].
These two data sets showed an alarming level of inconsist-
encies in an early study when microarray probes, due to
the lack of available probe sequence information, were
matched across platforms by Unigene IDs [16]. A higher
level of consistency was achieved in a subsequent study
following the release of probe sequence information by
Affymetrix [18]. The authors found a higher level of cross
platform consistency using only the subset of probe sets
that could effectively be sequence mapped to the same
Unigene entity as the corresponding cDNA clone. We
obtained similar results in a more limited cross platform
comparison study [4]. However, this strategy did not take
into consideration whether the short individual oligo
probes actually overlapped the corresponding cDNA
clone insert. Therefore, portions of the matched Affyme-
trix probe-sets could have been measuring different
regions or different splice variants of the target transcript
probed by the cDNA clone. This was perhaps the reason
that reproducing the clustering of the NCI-60 cell lines
required the highly biased supervised filtering of all genes
with a low level of consistency [18]. We introduced here a
further improvement that allowed us to rely solely on
sequence information and eliminated any further
supervised filtering based on expression data. Our strategy
relied on using expression signals from only those short
individual oligo probes that could be physically mapped
onto the corresponding cDNA clone insert. Furthermore,
this grouping was done irrespective of the default manu-
facturer-defined probe sets, in some cases combining
probes from several of them. This was much facilitated by
a recently introduced elegant computational tool that
allows the redefinition of an entire Affymetrix chip defini-
tion file within the framework of Bioconductor [21,22].
This strategy constitutes the highest level of sequence
based stringency for matching Affymetrix probe sets with
cDNA clones to date. Given the importance of correctly
designed probes, it is not surprising that this method pro-
vides the highest level of cross platform consistency at dif-
ferent levels of the analysis. In addition to the higher
levels of correlation, it also improved the transfer of clas-
sification results between breast cancer associated gene
expression data produced by different microarray
platforms.
Conclusion
We have shown that probes which target overlapping
transcript sequence regions on cDNA microarrays and
Affymetrix gene-chips exhibit a greater level of concord-
ance than the corresponding Unigene or sequence
matched features. Despite these promising results, we
should remain aware of the limitations of this method.
Microarray signals are a composite of three factors: 1) true
signal from the targeted gene, 2) cross-hybridization with
other genes, and 3) random noise. The stringent sequence
matching applied in this paper increases the consistency
of the first two factors across the platforms. However, it
does not allow for an easy deconvolution i.e. whether the
higher level of observed cross-platform consistency is due
to measurement of only the true signal or to reproduction
of the cross hybridization pattern. This determination will
require further studies underway in our laboratory.
Finally, the assumption that reference mRNA batches used
in cDNA hybridizations reflect the full level of diversity in
a target experimental mRNA population is imperfect.
Without access to measurements of this mRNA on the
experimental platform of interest, it is impossible to rep-
licate exactly the normalization inherent in a cDNA log
ratio. It is therefore important that the origin of the refer-
ence mRNA sample be kept prominently in mind when
considering the results of any cDNA microarray
experiment.
Methods
Inference of cDNA probe sequences
For a given cDNA clone, all corresponding read sequences
were extracted from dbEST [23]. When both 5' and 3' read
sequences were available for a given clone, these
sequences were BLASTed against the Acembly transcript
database corresponding to human genome build hg16.
The alignment results were used to construct a list of puta-
tive insert regions. If both clone read sequences had a
high-quality (expectation value < 0.001) hit in the correct
sense to a given transcript, the transcript region
comprising both read sequences and the flanked region is
predicted to be the clone sequence. Statistics for the
mapping of each cDNA microarray platform are summa-
rized in table 1.
Mapping of Affymetrix probes
For a given Affymetrix platform, all probe sequences as
obtained from Affymetrix were matched against the
Acembly transcript database. Only exact matches were
retained. Based on these results, we determined the
number of Affymetrix probes in each probe set that over-
lapped each predicted clone sequence.
In addition to assessing the extent of whole probe set-level
overlap with the clone sequence, we also constructedBMC Bioinformatics 2005, 6:107 http://www.biomedcentral.com/1471-2105/6/107
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alternative groupings of Affymetrix probes for each plat-
form. These redefined probe sets comprised all Affymetrix
probes that overlapped the corresponding cDNA clone,
whether or not those probes were intended to be a single
probe set by the manufacturer. In some cases, these probes
spanned several of the probe sets as defined by Affymetrix
(table 1). We then re-computed normalized expression
values for the datasets using these redefined probe sets
using the "altcdfenvs" package in Bioconductor [21,22].
Applying this strategy allowed us to use only those short
oligo probes that overlapped the corresponding cDNA
clone insert. The alternate probe mappings are available
in a format compatible with the "altcdfenvs" package [see
Additional file 1].
Normalization of Affymetrix data for comparison with 
cDNA microarray data
All raw Affymetrix probe-level measurements were first
transformed into log expression measures using RMA [8].
These expression measurements were then converted into
log ratios by subtracting the mean (log) expression from
each measurement. In all cases, this process was per-
formed for each sample with respect to its complete orig-
inal cohort. This was done to minimize artifacts resulting
from differences in RNA amplification, labeling, hybridi-
zation conditions, etc. cDNA log ratios for each gene were
mean centered with respect to the original data set.
NCI-60 concordance
Normalized cDNA microarray expression data for the
NCI-60 cell lines was obtained from a previous study [18].
The reference RNA batch for this study was derived from
"12 highly diverse cell lines of the 60" [19]. Raw CEL files
were obtained for the same cell lines run on the Affyme-
trix HuFL oligonucleotide expression platform [20] and
normalized as described above.
In addition to sequence-overlap methods of matching
measurements across the platforms, we also assessed the
weaker criterion of matching probes by Unigene
identifiers (build #175). Unigene clusters corresponding
to each probe set were obtained from Affymetrix (annota-
tion downloaded September 2004.) Clones on the cDNA
microarray were assigned to a Unigene cluster if that
cluster included an entry annotated as a read sequence for
the clone's IMAGE identifier.
Concordance was assessed by computing the Pearson cor-
relation coefficient between matched-pairs of both genes
and cell-lines across the two platforms. Genes were
excluded if more than 50 of the cDNA measurements for
that gene were missing. We also computed the average-
linkage Pearson correlation hierarchical clustering of the
combined datasets using both the Unigene and sequence-
overlap mappings.
Breast cancer classification
Previously described cDNA microarray expression meas-
urements from a cohort of breast cancer patients were
obtained for an 'intrinsic' gene set used to classify tumor
subtypes [7]. The original reference RNA batch used for
the cDNA study was derived from 11 different cultured
cell lines [24]. The samples were grouped into classes
corresponding to the five subtypes, and median centroids
were calculated for each class as described [7]. Putative
clone sequences for each clone on the microarray were
determined as described above.
Raw Affymetrix HG-U95Av2 CEL files were obtained for
199 samples from two additional cohorts of breast cancer
patients profiled in previous studies [9,10] and normal-
ized as described above. Each sample was then assigned to
the subtype corresponding to the median centroid for
which it attained the greatest Pearson correlation level, or
was designated "unclassified" if no correlation exceeded
0.1. The quality of the classification produced by both
mappings was evaluated by computing the average-link-
age Pearson correlation hierarchical clustering of the clas-
sified samples, based on the rationale that a more
meaningful classification should correspond to more
coherent sample-clusters consisting of each subtype.
Normal lung sample comparison
cDNA microarray data profiling of 5 normal lung samples
was obtained from a previous study of lung cancer [11].
The original reference RNA batch used for the cDNA study
was derived from 11 different cultured cell lines [24] (the
same reference as used in the breast cancer experiment.)
Affymetrix HG-U95Av2 CEL files were obtained from an
additional lung cancer study [12], 17 of which corre-
sponded to normal lung samples, and normalized as
described above. Cross-platform Unigene and sequence-
overlap based mappings were constructed as for the previ-
ous analyses. Genes were standard deviation filtered as
described for the NCI-60 analysis (min cDNA SD = 0.608,
min Affy SD = 0.271.) For each mapping, we calculated
the Pearson correlation between each of the 5 × 17 cross-
platform sample-pairs and compared the cumulative dis-
tributions (Fig 8). The significance of the observed
improvement in the redefined probe set mapping was
quantified using an exact one-sided Kolmogorov-Smirnov
test.
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Additional File 1
ZIP of 4 files allowing the remapping Affymetrix probe-sets described in 
this manuscript. These files can be used with the "altcdfenvs" package in 
Bioconductor to implement the redefinition of probe-sets based on 
sequence-matching with each of the 4 cDNA datasets described.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2105-6-107-S1.zip]